Virtus Biotech ETF BBP
104.16 USD -0.38 (-0.36%)
Nov 10, 2026, 10:16 AM EST
103.69 Day range 104.15
73.97 52-week range 110.05
- YTD
- +30.32%
- 1 year
- +38.85%
News
benzinga.com ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug ImmunityBio shares rise after the FDA accepted ANKTIVA's sBLA for NMIBC, with Phase 2/3 data showing durable bladder cancer outcomes.
benzinga.com ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check ImmunityBio stock dips despite Anktiva trial validation, FDA ad warning, and bullish analyst targets amid strong year-to-date gains.
benzinga.com ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use The NCCN adds ImmunityBio Anktiva plus BCG to bladder cancer guidelines, expanding treatment use and boosting outlook.
benzinga.com Why Is ImmunityBio Stock Soaring On Friday? ImmunityBio stock rises in premarket after NK cell therapy trials show safety and scalable production of billions of cells.
benzinga.com ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug ImmunityBio resubmits the ANKTIVA application to the FDA after a prior setback.
benzinga.com Why Is ImmunityBio Stock Gaining Tuesday? ImmunityBio shares climb in Tuesday's premarket after Saudi regulators encourage a key cancer treatment submission amid BCG shortages.
benzinga.com Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion Merck & Company, Inc. (MRK) to acquire SpringWorks Therapeutics, Inc. (SWTX) for $47/share in cash, creating synergies for rare tumor treatments and immediate revenue growth.
benzinga.com FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak.
benzinga.com 2 New Biotech ETFs Offer Unique Industry Focus